Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Chiome Bioscience's Enterprise Value for the quarter that ended in Jun. 2026 was 円4,929.9 Mil.
Chiome Bioscience's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-920.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chiome Bioscience EV-to-EBIT Related Terms
Chiome Bioscience EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Chiome Bioscience's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4583 vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Chiome Bioscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chiome Bioscience EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chiome Bioscience's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Chiome Bioscience's EV-to-EBIT falls into.
Chiome Bioscience's current Enterprise Value is 円5,429.0 Mil.
Chiome Bioscience's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-920.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chiome Bioscience (TSE:4583) has a EV-to-EBIT of -5.90 as of Aug. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Chiome Bioscience and its competitors. According to the industry distribution chart, Chiome Bioscience ranks #999999 out of 376 companies in the Biotechnology industry.
Is Chiome Bioscience's EV-to-EBIT too high?
Chiome Bioscience's current EV-to-EBIT is -5.90. Based on the distribution chart, Chiome Bioscience ranks #999999 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chiome Bioscience has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chiome Bioscience ranks #999999 out of 376 companies for EV-to-EBIT. This places Chiome Bioscience in the lower half of its industry. The industry median EV-to-EBIT is 16.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.28, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Chiome Bioscience and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chiome Bioscience's current EV-to-EBIT is -5.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Fairly Valued. The stock's GF Value™ is 円88.36, compared to a current price of 円83.00 — trading 6.1% below its estimated fair value. The current EV-to-EBIT is -5.90. Chiome Bioscience's overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current EV-to-EBIT is -5.90 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chiome Bioscience (TSE:4583) Overvalued in 2026?
Based on GuruFocus' analysis, Chiome Bioscience stock appears to be undervalued.
The current stock price of 円83.00 is trading 6.1% below its estimated GF Value™ of 円88.36.
GuruFocus considers Chiome Bioscience to be Fairly Valued.
Key valuation signals for TSE:4583:
EV-to-EBIT: -5.90
GF Value™: 円88.36 vs. price of 円83.00 (6.1% below fair value)
No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
52GF Score
Get the complete analysis for TSE:4583
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4583 has been successfully added to your 
